What Happened?
South San Francisco, CA-based Switch Therapeutics Resigned Si-ping Han as Chief Technology Officer
Date of management change: January 03, 2024
South San Francisco, CA-based Switch Therapeutics Resigned Si-ping Han as Chief Technology Officer
Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.
Si-ping Han is Chief Technology Officer at Switch Therapeutics. Previously, Si-ping held various senior IT leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Sinha Amiya, Kincade Maureen, Kaushik Saket, Lin Jungin, Schumann Tobias, Muniasamy Kandasamy, Stock James, Leakway Dylan, Murphy Jim, Talevi Chris, Parrillo Louis
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.